Summary & Overview
HCPCS J2998: Injection, Plasminogen, Human-TVMH, 1 mg
HCPCS Level II code J2998 denotes a 1 mg unit of recombinant human plasminogen injection (plasminogen, human-tvmh). As a biologic therapeutic code, it is relevant for clinicians and billing administrators managing care for patients requiring plasminogen replacement. Nationally, accurate use of J2998 affects coverage determinations, claims processing, and aggregate spending on specialty biologics.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and the clinical context for use. The publication provides benchmarks for unit-level billing and utilization where available, summaries of payer coverage patterns, and notes on coding considerations specific to a high-cost biologic therapy.
This summary serves clinical, coding, and policy audiences: it clarifies the code’s clinical purpose, lists the primary payers covered in the review, and outlines the types of insights included such as reimbursement benchmarks, policy updates, and operational considerations for billing and documentation. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J2998 represents Injection, plasminogen, human-tvmh, 1 mg. This code is used to report administration of a recombinant human plasminogen product supplied in 1 mg units. The service type is therapeutic biologic injection aimed at replacing or supplementing plasminogen levels. The typical site of service for billing with J2998 is an outpatient infusion or injection setting, which may include hospital outpatient departments, infusion centers, ambulatory surgical centers, or physician offices depending on payer and clinical context.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adolescent or adult with congenital plasminogen deficiency presenting with recurrent pseudomembranous conjunctivitis, ligneous conjunctivitis involving the ocular mucosa, or mucosal pseudomembrane formation in the oral or genital tract. The medication J2998 (injection, plasminogen, human-tvmh, 1 mg) is administered as a targeted biologic replacement therapy to restore plasminogen activity and promote fibrinolysis of pathologic membranes.
Clinical workflow:
-
Referral to a specialty clinic (ophthalmology, hematology, or multispecialty rare disease clinic) for confirmation of plasminogen deficiency and assessment of active membrane disease.
-
Pre-administration evaluation including review of prior plasminogen assays, allergy history, informed consent, and baseline vital signs.
-
Preparation of the injectable product under aseptic technique in a clinic infusion suite or outpatient procedure room; dosing individualized by specialist.
-
Administration via intravenous infusion or local tissue-directed application per prescribing guidance; observation for infusion reactions during and after administration.
-
Post-administration monitoring for efficacy (membrane resolution) and adverse events; coordination of follow-up care with ophthalmology, otolaryngology, or other affected specialties for re-treatment planning.